New report highlights the clinical, economic and societal value of cancer trials in Ireland
Cancer Trials Ireland has launched Value of Cancer Trials 2, a new report demonstrating the significant benefits of cancer clinical trials for patients, the health service and the wider Irish economy, while identifying opportunities to strengthen Ireland’s clinical research environment.
Launched on 6 November 2026, the report brings together clinical trial activity data, economic analysis, public attitudes research and insights from cancer specialists to build a compelling case for recognising clinical trials as an integral part of healthcare delivery.
The findings demonstrate considerable value already being generated through cancer clinical trials in Ireland, alongside significant potential to expand patient access, attract further international investment and improve the efficiency of clinical research.
Key findings from the report
€6.51 million in estimated healthcare savings through the avoidance of standard-of-care drug costs, based on 38 investigational medicinal product (IMP) trials involving 230 patients.
€6.76 million in estimated inward investment through investigational medicines, calculated from just 20 of those trials.
Approximately €10.5 million in potential hospital site-fee revenue, estimated using 423 patients recruited to IMP trials and an assumed average payment of €25,000 per patient.
A 44% increase in industry-sponsored clinical trials commencing in Ireland in 2025, across all disease areas. Despite this growth, Ireland ranked 14th of 27 EU Member States per capita.
Significant improvements in trial start-up performance, including a 65% reduction in median site agreement turnaround and a 32% reduction in ethics approval-to-activation timelines between Q4 2025 and Q2 2026.
